Overview

Tetanus is an acute medical condition characterized by prolonged, often painful muscle contractions and stiffness. Commonly known as "lockjaw," the disorder results from a bacterial toxin that interferes with normal nerve signaling to muscles. The disease is not transmitted from person to person; instead, infection follows contamination of wounds or breaches in the skin.

Cause and pathophysiology

The illness is produced when spores of the bacterium Clostridium tetani, which are ubiquitous in soil and animal feces, enter a suitable wound and germinate under anaerobic conditions. The bacterium releases a potent protein toxin called tetanospasmin, a well-known neurotoxin that travels along peripheral nerves to the central nervous system. There it blocks release of inhibitory neurotransmitters (principally GABA and glycine), disrupting the balance of excitation and inhibition that normally controls muscle contraction. As a result, affected muscles develop sustained involuntary contractions.

Typical presentation and complications

Symptoms usually appear after an incubation period of several days to a few weeks, depending on the location and severity of the wound. Early signs often include jaw stiffness (trismus), difficulty swallowing, and neck stiffness. As the condition progresses, patients may develop generalized rigidity, painful spasms, characteristic facial contractions sometimes called risus sardonicus, and back arching (opisthotonus).

  • Common local and generalized features: jaw tightness, muscle stiffness, and episodic spasms.
  • Autonomic instability: sweating, high blood pressure, and irregular heart rate can occur in severe cases.
  • Serious complications: fractures from forceful spasms, aspiration, and respiratory failure requiring ventilatory support.

Diagnosis and important distinctions

Diagnosis is primarily clinical and depends on the recognition of typical muscle findings together with a history of a wound or inadequate immunization. Laboratory culture of the bacterium is possible but often of limited value because the organism is fastidious and toxin detection is not routinely available in many settings. Tetanus differs from other causes of muscle rigidity because of its progression, characteristic spasms, and the absence of fever as a dominant feature early on.

Prevention and post‑exposure care

Vaccination with tetanus toxoid-containing vaccines is the cornerstone of prevention. Routine childhood immunization and periodic boosters in adolescence and adulthood maintain protective immunity. Maternal immunization prevents neonatal tetanus by transferring antibodies to the newborn. For wound management, proper cleaning and debridement reduce the chance of spore germination.

  • Active prevention: routine immunization schedules (primary series and boosters every 10 years in many countries).
  • Post‑exposure management: unvaccinated or incompletely vaccinated individuals may require both wound care and passive immunization; guidelines for post-exposure prophylaxis combine tetanus immune globulin and vaccine depending on history.

Treatment

Treatment aims to neutralize unbound toxin, control spasms, eradicate the bacteria, and provide supportive care. Clinicians may use human tetanus immune globulin to neutralize circulating toxin, administer antibiotics such as metronidazole to reduce bacterial load, and give sedatives or muscle relaxants to suppress spasms. Severe cases often need intensive care with airway protection and mechanical ventilation until the toxin effects abate.

Public health and history

Historically, tetanus was a frequent and feared cause of death after wounds and childbirth. The development and widespread use of tetanus vaccines dramatically reduced incidence in many parts of the world, but the disease persists, particularly where vaccine access is limited and where neonatal tetanus occurs after unclean delivery practices. Prevention through vaccination, safe delivery practices, and appropriate wound care remains the most effective strategy.

For general background and patient information about the disease itself see disease overview; for issues related to muscle symptoms consult resources on muscle disorders. Additional technical material about the toxin is available at specialist sources on tetanospasmin and neurotoxins.

Further clinical guidance and regional prevention policies can be found through public health documents and clinical practice guidelines referenced at pathogen information and vaccine advisory pages for immunization and post-exposure prophylaxis.